Mark Sheridan

Lower Grades Shift Attention to Explorers

As global grades fall and costs rise, genuine high-grade discoveries, particularly in safe jurisdictions, become disproportionately valuable.

Why Copper’s Supply Crunch is Becoming a Bull Market Catalyst

Surging demand from AI and electrification meets tightening supply, putting junior explorer Canterra Minerals in the investor spotlight.

Investor FAQs on Canterra Minerals High-Grade Success at Clementine Prospect

Canterra Minerals Corp. (TSX-V: CTM) (OTCQB: CTMCF) has provided investors with an update on high-grade success at its Clementine prospect.

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.